Search

Your search keyword '"Korb, Laura"' showing total 16 results
Start Over Author "Korb, Laura"
16 results on '"Korb, Laura"'

1. Psychotic Disorders

Author

Korb, Laura, Hassiotis, Angela, Bertelli, Marco O., editor, Deb, Shoumitro (Shoumi), editor, Munir, Kerim, editor, Hassiotis, Angela, editor, and Salvador-Carulla, Luis, editor

Published
2022
Full Text
View/download PDF

2. Aetiology and Pathogenesis

Author

Korb, Laura, Sheehan, Rory, Hassiotis, Angela, Bertelli, Marco O., editor, Deb, Shoumitro (Shoumi), editor, Munir, Kerim, editor, Hassiotis, Angela, editor, and Salvador-Carulla, Luis, editor

Published
2022
Full Text
View/download PDF

3. UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients

Author

Li, Adam, primary, Erridge, Simon, additional, Holvey, Carl, additional, Coomber, Ross, additional, Barros, Daniela, additional, Bhoskar, Urmila, additional, Crews, Matthieu, additional, Donnelly, Lorna, additional, Imran, Muhammad, additional, Korb, Laura, additional, Mwimba, Gracia, additional, Sachdeva-Mohan, Simmi, additional, Rucker, James J., additional, and Sodergren, Mikael H., additional

Published
2024
Full Text
View/download PDF

6. The potential for medicinal cannabis to help manage challenging behaviour in people with intellectual disability: A perspective review

Author

Korb, Laura, Tromans, Samuel, Perera, Bhathika, Khan, Nagina, Burrows, Lisa, Laugharne, Richard, Hassiotis, Angela, Allgar, Victoria, Efron, Daryl, Maidment, Ian, Shankar, Rohit, Korb, Laura, Tromans, Samuel, Perera, Bhathika, Khan, Nagina, Burrows, Lisa, Laugharne, Richard, Hassiotis, Angela, Allgar, Victoria, Efron, Daryl, Maidment, Ian, and Shankar, Rohit

Abstract

BACKGROUND: Around 2% of the population have intellectual disabilities. Over one-third people with intellectual disabilities (PwID) present with 'challenging behaviour', which nosologically and diagnostically is an abstract concept. Challenging behaviour is influenced by a range of bio-psycho-social factors in a population, which is unable to suitably comprehend and/or communicate concerns. This predisposes to poor health and social outcomes. There is no evidence-based treatments for managing challenging behaviour. Cannabidiol (CBD) and tetrahydrocannabinol (THC) are being trialled for a range of disorders, which are over-represented in PwID and provoke challenging behaviours, such as severe epilepsy, spasticity, post-traumatic stress disorder, social phobia, pain, etc. METHODS: This perspective review explores the different conditions, which benefit from medicinal CBD/THC preparations, by analysing recent literature from neurobiological, pre-clinical and clinical studies related to the topic. The evidence is synthesised to build an argument of the therapeutic benefits and challenges of medicinal cannabis to manage severe challenging behaviour in PwID. RESULTS: There is developing evidence of medicinal CBD/THC improving psychiatric and behavioural presentations in general. In particular, there is emergent proof in certain key areas of influence of medicinal CBD/THC positively supporting challenging behaviour, for example in children with neurodevelopmental disorders. However, there are significant challenges in employing such treatments in vulnerable populations such as PwID. CONCLUSION: Further clinical research for the considered use of medicinal CBD/THC for challenging behaviour management in PwID is needed. Strong co-production with experts with lived experience is needed for further testing to be done in this exciting new area.

Published
2023

7. Sleep: the neglected life factor in adults with intellectual disabilities.

Author

Korb, Laura, O’Regan, David, Conley, Jane, Dillon, Emma, Briggs, Rachel, Courtenay, Ken, and Perera, Bhathika

Subjects
*PEOPLE with intellectual disabilities, *SLEEP disorders, *MENTAL health
Abstract

Sleep is vital for our physical and mental health. Studies have shown that there is a high prevalence of sleep disorders and sleep difficulties amongst adults with intellectual disabilities. Despite this, sleep is often overlooked or its disorders are considered to be difficult to treat in adults with intellectual disabilities. There is a significant amount of research and guidance on management of sleep disorders in the general population. However, the evidence base for sleep disorders in adults with intellectual disabilities is limited. In this review paper, we look at the current evidence base for sleep disorders in adults with an intellectual disability, discuss collaborative working between intellectual disabilities psychiatrists and sleep medicine specialists to manage sleep disorders, and provide recommendations for future directions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. Statin prescription and CV risk assessment in adult psychiatric outpatients with intellectual disability

Author

Ho, Jamie Sin Ying, Collins, George, Rohra, Vikram, Korb, Laura, and Perera, Bhathika

Subjects
Prevention, cardiovascular diseases
Abstract

We performed a single-centre study to assess the risk of cardiovascular disease (CVD) in psychiatry outpatients with intellectual disability (ID) using the QRISK-3 score. There were 143 patients known to the ID psychiatry clinic enrolled. Of these, 28 (19.6%) had elevated CVD risk - defined as 10-year risk of heart attack or stroke of ≥10%. Of these, 57.1% were not prescribed statin therapy, which - after lifestyle measures - is recommended by National Institute for Health and Care Excellence (NICE) guidelines. The mean QRISK-3 score was 6.31% (95% confidence interval [CI] 4.84 to 7.78), with a relative risk of 3.50 (95%CI 2.34 to 4.67) compared with matched controls. The high CVD risk identified in this study supports routine CVD risk assessment and management in adult outpatients with ID. Appropriate lifestyle measures and statin therapy could help reduce the excess CVD-related morbidity and mortality in ID patients.

Published
2021

11. Patterns of comorbidity and psychopharmacology in adults with intellectual disability and attention deficit hyperactivity disorder: an UK national cross-sectional audit

Author

Perera, Bhathika, Chen, John, Korb, Laura, Borakati, Aditya, Courtenay, Ken, Henley, William, Tromans, Sam, and Shankar, Rohit

Abstract

ABSTRACTBackground: Attention-deficit hyperactivity disorder (ADHD) is higher in people with intellectual disability (ID) compared to the general population. Available limited evidence suggests this population has increased psychological problems, diagnostic overshadowing and psychotropic prescribing. This audit Identifies and analyzes real-world characteristics, diagnostic practices, treatment, and management of ADHD in adults with ID.Research Design and Methods:Pooled retrospective case note data for people with ID and ADHD, collected from 30 organizations across the UK, were analyzed. Patients were classified into mild and moderate-profound ID groups. Associated mental health and neurodevelopmental co-morbidity, Demographics, concomitant psychotropics, and mental and behavioral concerns were collected. Group differences were reported using logistic regression models.Results:Of 445 participants, 73% had co-occurring autism spectrum disorder (ASD) and 65% were prescribed ADHD medications. Those on ADHD medication were less likely to be prescribed antipsychotics (p < 0.001) and antidepressants (p < 0.001). Multiple significant differences were found in ADHD medication response between ID groups and those with/without co-morbid ASD but not associated with challenging behavior reduction.Conclusions:High levels of neurodevelopmental and psychiatric comorbidity were found. ID severity and the presence of ASD appear to influence the use of certain psychotropic medications. Appropriate use of ADHD medication appears to reduce psychotropic polypharmacy.

Published
2021
Full Text
View/download PDF

16. Statin prescription and CV risk assessment in adult psychiatric outpatients with intellectual disability.

Author

Ho JSY, Collins G, Rohra V, Korb L, and Perera B

Abstract

We performed a single-centre study to assess the risk of cardiovascular disease (CVD) in psychiatry outpatients with intellectual disability (ID) using the QRISK-3 score. There were 143 patients known to the ID psychiatry clinic enrolled. Of these, 28 (19.6%) had elevated CVD risk - defined as 10-year risk of heart attack or stroke of ≥10%. Of these, 57.1% were not prescribed statin therapy, which - after lifestyle measures - is recommended by National Institute for Health and Care Excellence (NICE) guidelines. The mean QRISK-3 score was 6.31% (95% confidence interval [CI] 4.84 to 7.78), with a relative risk of 3.50 (95%CI 2.34 to 4.67) compared with matched controls. The high CVD risk identified in this study supports routine CVD risk assessment and management in adult outpatients with ID. Appropriate lifestyle measures and statin therapy could help reduce the excess CVD-related morbidity and mortality in ID patients., Competing Interests: Conflicts of interest None declared., (Copyright © 2021 Medinews (Cardiology) Limited.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results